Title: Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid Organ
|
|
- Muriel Beatrice Ellis
- 6 years ago
- Views:
Transcription
1 AAC Accepted Manuscript Posted Online 3 July 2017 Antimicrob. Agents Chemother. doi: /aac Copyright 2017 American Society for Microbiology. All Rights Reserved Title: Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid Organ Transplant Patients Authors: 1. Ryan M Rivosecchi 1 2. Cornelius J Clancy 2,3,4 3. Ryan K Shields 2, 3 4. Christopher R Ensor 1,5 5. Michael A Shullo 1,5 6. Bonnie A Falcione 1,5 7. Raman Venkataramanan 6,7 8. # M. Hong Nguyen 2,3 Affiliations: 1. Department of Pharmacy & Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 2. Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 3. XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 4. VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania 5. Department of Pharmacy & Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 6. Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 7. Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania Corresponding Author: M. Hong Nguyen Professor of Medicine Director, Transplant Infectious Diseases and Antimicrobial Management Program University of Pittsburgh, ID Division 3550 Fifth Avenue, Suite S872 Scaife Hall Pittsburgh, PA nguyenh@dom.pitt.edu 31 Running Title: Isavuconazole interaction with tacrolimus 32
2 2 33 Abbreviations: 34 Cytochrome P450: CYP 35 Intravenous: IV 36 Invasive fungal infections: IFI 37 Interquartile: IQ 38 Model of End-Stage Liver Disease: MELD 39 Pharmacokinetic: PK 40 Solid organ transplant: SOT Tacrolimus concentration to dose ratio: C/D University of Pittsburgh Medical Center: UPMC Downloaded from on April 8, 2018 by guest
3 3 44 Abstract We evaluated the interaction between isavuconazole and tacrolimus among 55 organ transplant recipients. After isavuconazole discontinuation, tacrolimus concentration/dose normalized by weight (C/D) was reduced by 16%. Liver transplant recipients experienced the largest C/D reduction. A 1.3-fold decrease in tacrolimus daily dose was required to maintain desired tacrolimus levels. There was considerable inter-patient variability in the magnitude of the drug interaction. Tacrolimus doses should not be adjusted uniformly, but rather guided by therapeutic drug monitoring. Downloaded from on April 8, 2018 by guest
4 Antifungal prophylaxis is commonly administered following solid organ transplant (SOT) to prevent invasive fungal infections.(1) Tacrolimus, a primary immunosuppressive agent in SOT, is a substrate of cytochrome P450 (CYP) 3A4. The triazole antifungals are inhibitors of CYP3A4, which have varying effects on tacrolimus metabolism.(2, 3) The manufacturers of voriconazole and posaconazole recommend an empiric 1/3 reduction in the daily tacrolimus dose; however in clinical practice, the required reduction is often substantially greater.(4, 5) Isavuconazole acts as both a substrate and inhibitor of CYP3A4.(6-8) Currently, there are no definitive dosing recommendations for tacrolimus in patients receiving isavuconazole. Following a cluster of mucormycosis cases among SOT recipients at the University of Pittsburgh Medical Center (UPMC), universal isavuconazole prophylaxis was instituted [Table 1]. The objective of this study was to evaluate the effects of isavuconazole on whole blood trough tacrolimus concentrations in various SOT populations. We performed a retrospective study of consecutive patients who underwent SOT at UPMC between September 15, 2015 and February 10, 2016, and who were initiated on isavuconazole prophylaxis for 21 days. Patients were required to receive tacrolimus, have follow-up for 40 days after isavuconazole was stopped, and have whole blood tacrolimus concentrations measured during and following isavuconazole prophylaxis. Patients were excluded if they were on tacrolimus or other azoles at the time of transplantation, or required renal replacement therapy beyond the first 5 days after transplantation Fifty-five SOT recipients were included [Table 2]. Tacrolimus levels were obtained during (n=1,098) or following (n=3,080) isavuconazole prophylaxis. Tacrolimus
5 concentration/dose (C/D) ratios were normalized for body weight, and calculated by: [tacrolimus trough level/(total tacrolimus daily dose/actual body weight)].(9) While on isavuconazole, the median tacrolimus C/D was highest on day 4, reflecting the effects of isavuconazole loading doses [Figure 1]. C/D stabilized by day 8. The median tacrolimus C/D was higher among liver recipients than other organ recipients (p=0.002). C/D distributions showed wide variations within each of the transplant groups [Table 2]. After discontinuation of isavuconazole, median tacrolimus C/D gradually decreased, and stabilized at approximately 28 days [Figure 1]. In comparing tacrolimus C/D while on and off isavuconazole, ratios were considered at days 8 to 21 and days 28 to 60, respectively; these time points were selected based on our data above data [Figure 1], and to account for the prolonged half-life of isavuconazole (~80 to 100 hours).(6) Overall, the median tacrolimus C/D was higher on isavuconazole than off (125 and 120 (ng/ml)/(mg/kg), respectively); p=0.037). On a per-patient basis, tacrolimus C/D was reduced by a mean of 13% after isavuconazole discontinuation. Liver transplant recipients experienced the largest per-patient tacrolimus C/D reduction (36% vs. 8% in heart, 3% in lung and 1% in kidney recipients; p=0.047) [Figure 2]. Differences in tacrolimus C/D were not evident between SOT groups off isavuconazole (p=0.59). The median daily tacrolimus doses on and off isavuconazole were 6 and 8 mg, respectively [Table 2]. The corresponding median tacrolimus levels were 11 and 9 µg/ml, respectively. To estimate the potential tacrolimus dose for individual patients after discontinuing isavuconazole, we calculated the estimated tacrolimus daily dose off
6 isavuconazole as: (daily tacrolimus dose while on isavuconazole/(tacrolimus level on isavuconazole*tacrolimus level off isavuconazole)). The calculated value for all patients was 6.1 mg. The ratio of the median actual tacrolimus dose taken by the patients off isavuconazole to the calculated estimated tacrolimus dose was 1.3. In other words, tacrolimus dose was increased by a median of 1.3 fold after isavuconazole was discontinued. Age, race, sex, use of proton pump inhibitor, and liver transplantation were evaluated in univariate analyses to determine the association with tacrolimus C/D. Liver transplant was the only factor that was significantly associated with tacrolimus C/D among patients receiving isavuconazole (p=0.001). This association was no longer present after isavuconazole was discontinued (linear regression p=0.68). We used Model of End-stage Liver Disease (MELD) scores to assess the degree the liver dysfunction among liver transplant patients, and defined liver dysfunction as MELD score >10. The MELD scores for liver transplant patients while on and off isavuconazole were 11 and 7, respectively (p=0.0007). Fifty-six percent (10/18) and 17% (3/18) of liver transplant recipients had MELD scores >10, respectively (p=0.035), while on and off isavuconazole. Results did not differ if C/D ratios were not normalized by weight. To our knowledge, this is the first study that characterizes the interaction between isavuconazole and tacrolimus among SOT recipients. We used a population-based approach to evaluate the impact of isavuconazole on tacrolimus concentrations, which was feasible because of the large number of tacrolimus blood levels. Our results support three important conclusions. First, isavuconazole was associated with small but significant increases in tacrolimus levels among SOT recipients. Second, there was marked inter-patient variability in
7 tacrolimus levels. Finally, the interaction between isavuconazole and tacrolimus was more prominent among liver transplant patients than other SOT recipients Overall, the per-patient tacrolimus C/D was reduced a median of 13%, and the daily median tacrolimus dose to maintain specific tacrolimus levels was increased by 1.3-fold after isavuconazole was discontinued. Groll and colleagues demonstrated a 2.25-fold increase in tacrolimus concentrations when tacrolimus was administered 2 days after isavuconazole loading dose in healthy volunteers.(10) Although both Groll et al. and our study demonstrated that a drug-drug interaction exists between isavuconazole and tacrolimus (presumably through the inhibition of CYP3A4 by isavuconazole), the degree of drug interaction differed. Notably, our analysis was performed with isavuconazole at steady state in contrast to the loading phase in the Groll study; studying the change in tacrolimus C/D while isavuconazole concentrations were at steady-state provided a more accurate depiction of the magnitude of the drug-drug interaction. Moreover, Groll included healthy, young (mean age: 35 years) volunteers who were on no other drugs, whereas our patients were older (mean age: 60 years), critically ill, and within a month of transplant. Our results, combined with the considerable inter-patient variability in the magnitude of the drug interaction,(11) suggest that tacrolimus should not be administered using uniform dose reductions among patients receiving isavuconazole, but rather guided by therapeutic drug monitoring. This conclusion differs from the standard dose reductions that are recommended when initiating or discontinuing voriconazole or posaconazole.(4, 5)
8 Our finding that the interaction between isavuconazole and tacrolimus differed by transplanted organ was novel. Indeed, the 13% decrease in tacrolimus C/D among our entire cohort following discontinuation of isavuconazole was driven largely by a 36% decrease among liver transplant patients; no other organ had a significant difference in tacrolimus C/D after isavuconazole was stopped. If liver transplant patients are removed from the cohort, the perpatient decrease in tacrolimus C/D was only 3%. MELD scores were higher within the first 4 weeks of liver transplantation (while patients were on isavuconazole prophylaxis) than thereafter (p=0.0007), suggesting that abnormal liver function may have accounted for the association with tacrolimus C/D. Indeed, metabolism of isavuconazole and tacrolimus through the CYP3A4 pathway, which is known to exhibit both inter- and intrapatient variability after liver transplantation, was likely impaired during the time the patients were receiving both agents.(12) Isavuconazole clearance is decreased in patients with moderate hepatic dysfunction, leading to a near doubling of half-life after a single dose.(13) Desai and colleagues demonstrated a doubling of mean isavuconazole trough levels in patients with mild or moderate hepatic dysfunction.(14) Of note, the difference in tacrolimus C/D between organs was no longer apparent 8 weeks after liver transplant, which may be attributable to recovery of hepatic function in the liver transplant patients. In the future, studies of isavuconazole pharmacokinetic (PK) following liver transplantation and other SOT are needed Isavuconazole is characterized by a large volume of distribution and prolonged half-life after multiple administrations.(15, 16) In a dose-finding PK study, Schmitt-Hoffmann and colleagues noted a ~4- to 5-fold accumulation factor between the first and final day (day 14 or 21) of isavuconazole administration, and steady-state volume of distribution of 308 to 542
9 liters.(17) Based on a systemic clearance of 2.4 to 4.1 liters/hour in healthy volunteers, effects of isavuconazole would be expected to last for 75 to 226 hours after discontinuation.(17) Our SOT patients had persistently elevated tacrolimus C/D ratios >600 hours after stopping isavuconazole (Figure 1). The differences between our data and those of Schmitt-Hoffmann could be due to the longer course of isavuconazole in this study, with all patients receiving the drug for 1 month. We acknowledge that our results may not be generalizable to patient populations other than SOT recipients, or to SOT recipients at other centers. Since isavuconazole levels were not evaluated, we were unable to determine if differences in isavuconazole concentrations may have been responsible for variations in tacrolimus C/D. In conclusion, the interaction between isavuconazole and tacrolimus is most significant following liver transplantation, and relatively modest following other SOT. However, the impact of isavuconazole on tacrolimus levels varies significantly between individuals undergoing each type of transplant. In our program, we currently recommend against standardized tacrolimus dose reductions. Rather, we advocate close tacrolimus TDM until levels are stable, and such time that isavuconazole levels are likely to have reached steady state (~7 days). Programs should devise their own protocols for tacrolimus therapeutic drug monitoring (TDM) upon initiation of isavuconazole, based on types of organ transplant and local experience. A complete PK analysis, including isavuconazole levels, is warranted to further define drug interactions Acknowledgements. The authors would like to acknowledge the assistance of Lloyd Clark. C. J. C. receives support from the U. S. Department of Veterans Affairs (1IO1BX001955) and National
10 Institutes of Health (AI111037, AI121555, AI126157). R. K. S. (K08AI114883) and M. H. N. (AI107290, AI128338) receive support from the National Institutes of Health. All authors contributed to the design, data collection, analysis, and manuscript preparation Disclosures. This project was funded by investigator-initiated research grants to C. J. C. and M. H. N. from Astellas Pharma, Inc. C. J. C. and M. H. N. have participated in an advisory board for Astellas Pharma, Inc. Downloaded from on April 8, 2018 by guest
11 References 1. Singh N Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis 39 Suppl 4:S Nivoix Y, Ubeaud-Sequier G, Engel P, Leveque D, Herbrecht R Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab 10: Zhang S, Pillai VC, Mada SR, Strom S, Venkataramanan R Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica 42: Anonymous. VFend(R)[Package Insert]. Roerig/Pzifer Inc, New York, NY; Accessed 5. Anonymous. Noxafil(R)[Package Insert] Merck & Co, INC., Whitehouse Station, NJ; Accessed 6. Anonymous. Cresemba(R) [Package Insert] Astellas Pharma US, Inc., Northbrook, IL; Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR, 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Racil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JA, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJ, Vital, FungiScope Mucormycosis I Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 16: Maertens JA, Raad, II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR, 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387: Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 44: Groll AH, Desai A, Han D, Howieson C, Kato K, Akhtar S, Kowalski D, Lademacher C, Lewis W, Pearlman H, Mandarino D, Yamazaki T, Townsend R Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults. Clin Pharmacol Drug Dev doi: /cpdd Kim T, Jancel T, Kumar P, Freeman AF Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring. J Clin Pharm Ther doi: /jcpt Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, Perkins JD, et al Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271: Schmitt-Hoffmann A, Roos B, Spickermann J, Heep M, Peterfai E, Edwards DJ, Stoeckel K Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother 53:
12 Desai A, Schmitt-Hoffmann AH, Mujais S, Townsend R Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment. Antimicrob Agents Chemother 60: Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, Brown T, Roehrle M Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 50: Cornely OA, Bohme A, Schmitt-Hoffmann A, Ullmann AJ Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother 59: Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, Roehrle M, Beglinger C Single-ascending-dose pharmacokinetics and safety of the novel broadspectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 50: Wallemacq PE, Verbeeck RK Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 40:
13 Table 1. Tacrolimus dosing protocols and duration of isavuconazole prophylaxis according to organ transplant Initial target Duration of Initial dosage of concentration range of isavuconazole tacrolimus tacrolimus 1 prophylaxis Kidney transplant 2 mg every 12 hours 8 to 12 ng/ml 1 month Liver transplant 1 mg every 12 hours 8 to 10 ng/ml 1 month Heart transplant 2 mg every 12 hours 10 to 12 ng/ml 1 month Lung transplant 0.5 mg every 12 hours 12 to 15 ng/ml 3 to 4 months This table summarizes standard recommendations at UPMC at the time of this study. Isavuconazole was dosed according to manufacturer recommendations.(6) 1 There were no changes in target tacrolimus levels throughout the study period. Tacrolimus levels were measured using high-performance liquid chromatography mass spectrometry.
14 Table 2. Clinical characteristics of patients included in this study All patients (n=55) Kidney transplant (n=20) Liver transplant (n=18) Heart transplant (n=9) Lung transplant (n=8) P-value Median age in years (range) 60 (22-74) 53.5 (22-74) 60.5 (43-69) 64 (58-69) 66 (56-68) Male, n (%) 47 (85) 17 (85) 13 (72) 7 (78) 7 (88) 0.73 Race: white, n (%) Median weight in kilograms (range) Body mass index (range) Concomitant PPI, n (%) Duration of intravenous therapy, days 1 Median tacrolimus C/D 2 (interquartile range) Median tacrolimus daily dose in mg (IQ range) 46 (84) 16 (80) 15 (83) 7 (78) 7 (88) (52-180) 28 (13 41) 93 (65-146) 30 (25 41) 88 ( ) 30 (21 40) 77 ( ) 26 (19 31) 69 (60-74) 23 (17 27) (78) 16 (80) 14 (78) 5 (63) 8 (100) (0-21) 2 (0-4) 5 ( 0-18) 5 (3-21) 10 (6-21) < (94 188) On isavuconazole, day (76 181) 6 (4-10) 7.5 ( ) 192 ( ) 105 (84 150) 4 (2.75-6) 7.5 ( ) 106 (80 109) 8.5 (5.5-10) < Median tacrolimus trough levels in 10.5 ( ) 10.5 ( ) 8.5 ( ) 12 (9.7-14) 12.5 ( ) 0.001
15 15 ng/ml (IQ range) Off isavuconazole, day Median tacrolimus C/D (interquartile range) 120 (62 171) 154 (59 187) 101 (60 161) 103 (79 154) 87 (38 163) Median tacrolimus daily dose in mg (IQ range) Median tacrolimus trough levels in ng/ml (IQ range) Median actual tacrolimus dose taken off isavuconazole / calculated estimated tacrolimus dose 3 8 (5-10) 6.5 ( ) 9 (7-11_ 7 (6-9.5) 11 ( ) 1.3 ( ) 6 (4-8) 9.5 ( ) 11 ( ) 9.5 ( ) 11 ( ) 1.3 ( ) 1.9 ( ) 1.1 ( ) 1.4 ( ) 1 Patients initiated on oral therapy were considered to have zero days of intravenous therapy The patient s actual body weight on the day of isavuconazole initiation was used throughout the C/D analysis. The total daily dose was calculated as an average of doses (mg) for the day the tacrolimus level was assayed and two days prior; this calculation was chosen to account for the ~12 hour half-life of tacrolimus.(18) 3 The calculated estimated tacrolimus daily dose off isavuconazole was defined as (daily tacrolimus dose while on isavuconazole / (tacrolimus level on isavuconazole * tacrolimus level off isavuconazole)).(9) PPI = proton pump inhibitor, C/D = concentration to dose ratio (ng/ml)/(mg/kg) 0.28
16 Tacrolimus C/D ratio Tacrolimus C/D ratio Figure 1: Tacrolimus concentration/dose ratios of solid organ transplant patients. Individual diamonds represent median tacrolimus C/D ratio for all patients at indicated times. Tacrolimus C/D ratios were evaluated after the first full day of isavuconazole and tacrolimus therapy (i.e., post-operative day 2). Figure 1A: On isavuconazole prophylaxis Days after starting isavuconazole and tacrolimus Figure 1B: Off isavuconazole prophylaxis (stopped on day 0) Weeks after discontinuation of isavuconazole Figure 2. Tacrolimus C/D (median + interquartile range) on and off isavuconazole stratified by type of organ transplant.
17 C o n c e n tr a tio n /d o s e (n g /m L )/(m g /k g ) C o n c e n tr a tio n /d o s e (n g /m L )/(m g /k g ) Figure 2A: Tacrolimus C/D on isavuconazole. Tacrolimus C/D was higher among liver transplant patients (median: 191.8) than kidney (123.7, p=0.046), heart (104.7, p=0.02) and lung transplant patients (106.3, p=0.01) K id n e y L iv e r H e a r t L u n g s Figure 2B: Tacrolimus C/D off isavuconazole. There was no difference in tacrolimus C/D among types of organ transplant patients (p=0.59) K id n e y L iv e r H e a r t L u n g s 288
18
Outcomes by Minimum Inhibitory Concentrations for Patients Treated with Isavuconazole
AAC Accepted Manuscript Posted Online 29 October 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.01634-18 Copyright 2018 Andes et al. This is an open-access article distributed under the terms of the
More informationClinical Study Tacrolimus Dose odi cation in Hematopoietic Cell Transplant Recipients Following a Change in Therapy from Fluconazole to Voriconazole
ISRN Transplantation Volume 2013, Article ID 281285, 5 pages http://dx.doi.org/10.5402/2013/281285 Clinical Study Tacrolimus Dose odi cation in Hematopoietic Cell Transplant Recipients Following a Change
More informationReceived 9 March 2009/Returned for modification 23 June 2009/Accepted 3 August 2009
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2009, p. 4885 4890 Vol. 53, No. 11 0066-4804/09/$12.00 doi:10.1128/aac.00319-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Effect
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationAntimykotische Therapie und TDM: ECIL 6 Guidelines
Antimykotische Therapie und TDM: ECIL 6 Guidelines Disclosures Grants Gilead, Merck, Sharp & Dohme, Pfizer Consultant Amplyx, Astellas, Basilea, Gilead, Merck, Sharp & Dohme and Schering-Plough Speakers
More informationAntimykotische Therapie und TDM: ECIL 6 Guidelines
Antimykotische Therapie und TDM: ECIL 6 Guidelines Disclosures Grants Gilead, Merck, Sharp & Dohme, Pfizer Consultant Amplyx, Astellas, Basilea, Gilead, Merck, Sharp & Dohme and Schering-Plough Speakers
More information9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure
Faculty Overcoming Challenges in the Management of Invasive Fungal James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Departments of Pharmacy and Infectious
More informationKeywords ethinyl estradiol/norethindrone, isavuconazole, ketoconazole, midazolam, rifampin
Original Manuscript Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/ Norethindrone in Healthy Adults Clinical Pharmacology
More informationEvidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures
Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections Presenter James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University
More informationPharmacokinetic and Pharmacodynamic Evaluation of the Drug-Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects
Original Manuscript Pharmacokinetic and Pharmacodynamic Evaluation of the Drug-Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects Clinical Pharmacology in Drug Development 2017, 6(1)
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationIsavuconazole. Lepak et al 2013 Antimicrob Agents Chemother 57: Lepak et al 2013 Antimicrob Agents Chemother 57:
Priv.-Doz. Dr. med. Maria J.G.T. Vehreschild Department I of Internal Medicine Clinical Trials Unit II Infectious Diseases Research Group Clinical Microbiome Isavuconazole 09.07.2017 Maria J.G.T. Vehreschild
More informationESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole
Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole J.A. Maertens, hematologist, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Current guidelines: first-line
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationManagement Strategies For Invasive Mycoses: An MD Anderson Perspective
Management Strategies For Invasive Mycoses: An MD Anderson Perspective Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA Professor of Medicine Director of Mycology Research Program M. D. Anderson Cancer
More informationInvasive Fungal Infections in Solid Organ Transplant Recipients
Outlines Epidemiology Candidiasis Aspergillosis Invasive Fungal Infections in Solid Organ Transplant Recipients Hsin-Yun Sun, M.D. Division of Infectious Diseases Department of Internal Medicine National
More informationPosaconazole levels in patients taking the delayed-release tablet versus the oral suspension:
AAC Accepted Manuscript Posted Online 8 June 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.00496-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 Posaconazole levels
More informationCYP2C19 VRCZ (TDM) VRCZ mg/ml mg/ml 8.61 mg/ml AST ALT mg/ml PM VRCZ CYP2C19 TDM (VRCZ)
June 2010 THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 255 ( 49 ) CYP2C19 1,2) 1) 1,2) 1,2) 2) 1) 1) 2) 2010 1 4 (voriconazole; VRCZ) CYP2C19 CYP3A4 CYP2C9 20% CYP2C19 (PM) PM VRCZ (TDM) VRCZ 15 VRCZ CYP2C19
More informationCombination Antifungal Therapy for Invasive Pulmonary Aspergillosis in a Heart Transplant Recipient
case report Combination Antifungal Therapy for Invasive Pulmonary Aspergillosis in a Heart Transplant Recipient Andres Beiras-Fernandez, 1 * Amir K. Bigdeli, 1 * Thomas Nickel, 2 Sebastian Michel, 1 Peter
More informationIsavuconazole Population Pharmacokinetic Analysis Using Non-Parametric. Estimation in Patients with Invasive Fungal Disease: Results from the VITAL
AAC Accepted Manuscript Posted Online 16 May 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.00514-16 Copyright 2016 Kovanda et al. This is an open-access article distributed under the terms of the
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationChallenges and controversies of Invasive fungal Infections
Challenges and controversies of Invasive fungal Infections Mona Al-Dabbagh, MD, MHSc Assistant Professor of Pediatrics, COM-KSAU-HS Consultant Pediatric Infectious Diseases and Transplant Infectious Diseases
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationOriginal Manuscript. Keywords atorvastatin, digoxin, isavuconazole, metformin, methotrexate
Original Manuscript Pharmacokinetic Interactions Between and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects Clinical Pharmacology in Drug Development
More informationHow To Use PK/PD Of Antifungal Drugs In Clinical Practice?
How to use PK/PD of antifungal drugs in clinical practice? Dr Atul Patel, MD, FIDSA Chief Consultant and Director Infectious Diseases Clinic Vedanta Institute of Medical Sciences Ahmedabad, India How To
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February
BRAND NAME Prevymis TM GENERIC NAME Letermovir MANUFACTURER Merck & Co., Inc. DATE OF APPROVAL November 9, 2017 PRODUCT LAUNCH DATE TBD REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of new
More informationAntifungal therapy guidelines
Background Invasive fungal infections (IFI) can cause significant morbidity and mortality among patients with haematological malignancies. There is good evidence for the use of antifungal prophylaxis in
More informationNo Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany
Is Combined Antifungal Therapy More Efficient than Single Agent Therapy? No Evidence As Yet www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam,
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Vfend /Voriconazole
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationNew Directions in Invasive Fungal Disease: Therapeutic Considerations
New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman
More informationPrimary prophylaxis of invasive fungal infection in patients with haematological diseases
Primary prophylaxis of invasive fungal infection in patients with haematological diseases Tunis, May 24 2012 Important questions for antifungal prophylaxis Who are the patients at risk? Which is the risk:
More informationTherapeutic Drug Monitoring in Antifungal Therapy. Why, When and How
Therapeutic Drug Monitoring in Antifungal Therapy Why, When and How Roger Brüggemann Radboud University Nijmegen Medical Centre and Nijmegen Institute for Infection, Inflammation and Immunology (N4i) Trends
More informationEvaluation of hypokalemia and potassium supplementation during administration of liposomal amphotericin B
EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 941-946, 2014 Evaluation of hypokalemia and potassium supplementation during administration of liposomal amphotericin B EISEKI USAMI 1, MICHIO KIMURA 1, TETSUFUMI
More informationProphylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?
TIMM-4 18-21 October 2009 Athens, Greece Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2011 April 6.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1991 December ; 23(6): 2777 2779. Pharmacokinetics of Cyclosporine and Nephrotoxicity in Orthotopic Liver Transplant
More informationTherapeutic Options: Where do we stand? Where do we go?
Therapeutic Options: Where do we stand? Where do we go? Oliver A. Cornely MD, FACP, FIDSA, FAAM Chair, Translational Research, CECAD Cluster of Excellence Deputy Head, Division of Infectious Diseases Director,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Noxafil) Reference Number: AZ.CP.PHAR.30 Effective Date: 11.16.16 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationEvaluation of Plasma Concentration and Hepatotoxicity of Voriconazole in Pediatric Patients following Hematopoietic Stem Cell Transplantation
2016 Evaluation of Plasma Concentration and Hepatotoxicity of Voriconazole in Pediatric Patients following Hematopoietic Stem Cell Transplantation Hamidreza Taghvaye Masoumi 1, Molouk Hadjibabaie 1, Morvarid
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationIsavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
REVIEWS OF ANTI-INFECTIVE AGENTS INVITED ARTICLE Louis D. Saravolatz, Section Editor Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent Marisa H. Miceli 1 and Carol A. Kauffman 1,2 1 Division
More informationArticles. Funding Astellas Pharma Global Development, Basilea Pharmaceutica International.
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial Johan
More informationI am against to TDM in critically ill patient
TDM I am against to TDM in critically ill patient TDM of antifungals: where are we? Dr. Rafael Zaragoza Antifungal therapy in ICU; prophylaxis, pre-emptive and targeted Conflicts of interest: Pfizer Astellas
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationOptimal Management of Invasive Aspergillosis in the Context of New Guidelines in High Risk Haematological Patients
Optimal Management of Invasive Aspergillosis in the Context of New Guidelines in High Risk Haematological Patients Shariq Haider Professor Medicine McMaster University Conflict of Interest Disclosure Slide
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationRole of isavuconazole in the treatment of invasive fungal infections
Therapeutics and Clinical Risk Management open access to scientific and medical research Open Access Full Text Article Review Role of isavuconazole in the treatment of invasive fungal infections Dustin
More informationTherapy of Hematologic Malignancies Period at high risk of IFI
Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 September 22.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1990 February ; 22(1): 57 59. Effect of Hepatic Dysfunction and T Tube Clamping on FK 506 Pharmacokinetics and Trough
More informationOptimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology
ATHENA 2017 International Conference November 28 30, 2017 Optimizing antifungal dosing regimens Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology Clinical Microbiology Laboratory, «Attikon»
More informationPosaconazole therapeutic drug monitoring in a regional hospital setting
University of Wollongong Research Online Faculty of Science, Medicine and Health - Papers Faculty of Science, Medicine and Health 2016 Posaconazole therapeutic drug monitoring in a regional hospital setting
More informationSolid organ transplant patients
M.6 Meet-the-expert sessions Solid organ transplant patients Martin Iversen, Denmark José M. Aguado, Spain Copenhagen, Sunday 13 October 2013 Conflict of interest disclosure In the past 5 years, J.M.A.
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationUse of Antifungals in the Year 2008
Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis
More informationOpen Forum Infectious Diseases Advance Access published February 11, 2016
Open Forum Infectious Diseases Advance Access published February 11, 2016 1 A Critical Reappraisal of Prolonged Neutropenia as a Risk Factor for Invasive Pulmonary Aspergillosis Michael S. Abers 1,2, Musie
More informationADVANCES AND CHALLENGES IN HEMATOLOGY. Invasive fungal disease management in febrile neutropenia
16 th Annual Meeting of Saudi Society of Hematology 7 th Pan Arab Hematology Association Congress ADVANCES AND CHALLENGES IN HEMATOLOGY Invasive fungal disease management in febrile neutropenia J.A. Maertens,
More informationESCMID Online Lecture Library. by author
The antibacterial experience: indications for clinical use of antimicrobial combinations To prevent the emergence of resistant organisms (tuberculosis) To treat polymicrobial infections (abdominal complicated
More informationCurrent challenges in triazole TDM
Current challenges in triazole TDM Isabel Spriet, PharmD PhD Clinical Pharmacology and Pharmacotherapy, University Hospitals Leuven & KU Leuven, Belgium Background Triazoles are the most widely prescribed
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationBroad spectrum triazoles: which drug and when?
Broad spectrum triazoles: which drug and when? Martin Hoenigl, PD, MD, FECMM Section of Infectious Diseases and Tropical Medicine, Department of Medicine, Medical University Graz, Austria AND Division
More informationIn Vitro Interactions of Antifungal agents and Tacrolimus against Aspergillus Biofilms
AAC Accepted Manuscript Posted Online 24 August 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.01510-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 In Vitro Interactions
More informationTailored Antifungal Modification in Breakthrough Mold Infections. Russell E. Lewis University of Bologna
Tailored Antifungal Modification in Breakthrough Mold Infections Russell E. Lewis University of Bologna 45 year-old patient with AML and documented pulmonary aspergillosis during remissioninduction chemotherapy
More informationmycoses Prospective antifungal therapy (PATH) alliance â : focus on mucormycosis Summary Introduction
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article Prospective antifungal therapy (PATH) alliance â : focus on mucormycosis Dimitrios P. Kontoyiannis, 1 Nkechi Azie, 2 Billy
More informationCancer Medicine. Introduction. Open Access ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology oncology patients: a retrospective cohort study Hsiang-Chi
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Maertens JA, Raad II, Marr KA, et al. Isavuconazole
More informationAmphotericin B Lipid Complex (Abelcet ) 05/06
Amphotericin B Lipid Complex (Abelcet ) Structure and Activity AMB : DMPC : DMPG lipid complex, 10:7:3 mol:mol ribbon-like lipid structures, 1.6-11 µm in diameter binds to ergosterol disturbance of cell
More informationSummary of the risk management plan (RMP) for Cresemba (isavuconazole)
EMA/576866/2015 Summary of the risk management plan (RMP) for Cresemba (isavuconazole) This is a summary of the risk management plan (RMP) for Cresemba, which details the measures to be taken in order
More informationHIV and transplant: obstacles and opportunities
HIV and transplant: obstacles and opportunities Christine Durand, M.D. 18 de abril de 2013, XI Conferência Brasil Johns Hopkins University em HIV/AIDS Outline Part 1: Solid organ transplant (SOT) Part
More informationDepartment of Pediatric Hematology/Oncology, University Children s Hospital Tübingen, Hoppe-Seyler-Strß 1, Tübingen, Germany 2
Case Reports in Transplantation Volume 2012, Article ID 672923, 4 pages doi:10.1155/2012/672923 Case Report Eradication of Pulmonary Aspergillosis in an Adolescent Patient Undergoing Three Allogeneic Stem
More informationHow Can We Tailor Antifungal Therapy?
How Can We Tailor Antifungal Therapy? Russell Lewis Infections Diseases Unit Department of Medical Sciences and Surgery S.Orsola Malpighi Hospital University of Bologna Most Common Infectious Diagnosis
More informationNew antifungal agents
New antifungal agents Dr Atul Patel, MD, FIDSA Chief Consultant and Director Infectious Diseases Clinic Vedanta Institute of Medical Sciences Ahmedabad, India Presented at MMTN Malaysia Conference 5 6
More informationPrevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study
Kontoyiannis et al. BMC Infectious Diseases (2016) 16:730 DOI 10.1186/s12879-016-2023-z RESEARCH ARTICLE Prevalence, clinical and economic burden of mucormycosis-related in the United States: a retrospective
More informationAPX001 A novel broad spectrum antifungal agent in development for the treatment of invasive fungal infections
APX001 A novel broad spectrum antifungal agent in development for the treatment of invasive fungal infections TIMM, Belgrade, Serbia October, 2017 New antifungal drugs in the pipeline S15 Dr. Michael Hodges
More informationWhat have we learned about systemic antifungals currently available on the market?
2nd ECMM/CEMM Workshop Milano, September 25, 2010 What have we learned about systemic antifungals currently available on the market? Prof. Dr. Georg Maschmeyer Dept. of Hematology, Oncology & Palliative
More informationA Clinically Significant Interaction Between Tacrolimus and Multiple Proton Pump Inhibitors in a Kidney Transplant Recipient
Cedarville University DigitalCommons@Cedarville Pharmacy Practice Faculty Publications Department of Pharmacy Practice - A Clinically Significant Interaction Between Tacrolimus and Multiple Proton Pump
More informationTitle: Cefoxitin Continuous Infusion for Lung Infection Caused by M. abscessus group
AAC Accepts, published online ahead of print on 14 April 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.02763-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 Title: Cefoxitin
More informationIsavuconazonium sulfate (Cresemba, Astellas Pharma US Inc.) June 2017 Non-Formulary
Isavuconazonium sulfate (Cresemba, Astellas Pharma US Inc.) June 2017 Non-Formulary Criteria for Formulary Consideration of Isavuconazonium Sulfate Efficacy Isavuconazonium is approved by the FDA for treatment
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationEpidemiology of Cryptococcosis and Cryptococcal Meningitis in a large retrospective cohort of patients after solid organ transplantation
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2017 Epidemiology of Cryptococcosis and Cryptococcal Meningitis in a large retrospective cohort of patients after
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationDiagnosis,Therapy and Prophylaxis of Fungal Diseases
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance â registry David L. Horn, 1 Alison
More informationReceived 22 November 2007/Returned for modification 29 December 2007/Accepted 12 January 2008
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2008, p. 1396 1400 Vol. 52, No. 4 0066-4804/08/$08.00 0 doi:10.1128/aac.01512-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. In Vitro
More informationReducing the antifungal drugs consumption in the ICU
Reducing the antifungal drugs consumption in the ICU Philippe Montravers Département d Anesthésie et Réanimation Chirurgicale CHU Bichat Claude Bernard Pole TCAUR, HUPNVS Assistance Publique-Hôpitaux de
More informationamphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET
4 17 9 27 17 1 7 amphotericin B 34 empiric therapy; ET preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET Key words: antifungal therapyempiric therapypreemptive
More informationApplication of PK/PD concepts and the role of TDM in the management of patients with fungal disease. The role of combination therapy as of May 2011
Application of PK/PD concepts and the role of TDM in the management of patients with fungal disease The role of combination therapy as of May 2011 Claudio Viscoli, MD Professor of Infectious Disease Chief,
More informationUpdates and practical guide on antifungal agents
Updates and practical guide on antifungal agents Dr Atul Patel, MD, FIDSA Chief Consultant and Director Infectious Diseases Clinic Vedanta Institute of Medical Sciences Ahmedabad, India Presented at MMTN
More informationTreatment Guidelines for Invasive Aspergillosis
Treatment Guidelines for Invasive Aspergillosis Thomas F. Patterson, MD Professor of Medicine Director, San Antonio Center for Medical Mycology The University of Texas Health Science Center at San Antonio
More informationNewer Combination Therapies
Newer Combination Therapies William J. Steinbach, MD Associate Professor of Pediatrics, Molecular Genetics & Microbiology Pediatric Infectious Diseases Duke University Medical Center Combination Therapy
More informationAspergillosis in the critically ill patient
Aspergillosis in the critically ill patient José Artur Paiva Director of Emergency and Intensive Care Department Centro Hospitalar São João Porto Associate Professor of Medicine University of Porto Infection
More information8/24/2015. Objectives (Pharmacists) Azoles: Mechanism of action. Objectives (Technicians)
Objectives (Pharmacists) Invasive fungal infections: What to do if there s a fungus among us Nick O Donnell, PharmD, BCPS Infectious Diseases Pharmacotherapy Fellow List three important interactions and
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More information2/4/14. Disclosures. Learning Objective
Pharmacogenetic Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplants Ashley Teusink, PharmD, MBA, BCPS, Alexander Vinks, Kejian Zhang,
More informationLiposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients
ORIGINAL ARTICLE MYCOLOGY Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients K. Bochennek 1, L. Tramsen 1, N. Schedler 1, M. Becker 1, T. Klingebiel
More information